INTRODUCTION

This month has seen stimulating growth, increased market shares and opportunity for innovation in the form of key mergers and acquisitions. Below, we’re listing down our top 4 picks for eye catching mergers and acquisitions in the MedTech Industry.

1. Johnson & Johnson to Acquire Abiomed

Johnson & Johnson, the world’s largest, most diversified healthcare products company, and Abiomed, a world leader in breakthrough heart, lung and kidney support technologies, announced their partnership by entering into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Abiomed, for an upfront payment of $380.00 per share in cash, corresponding to an enterprise value of approximately $16.6 billion which includes cash acquired.

The acquisition broadens Johnson & Johnson MedTech’s position as a growing cardiovascular innovator, advancing the standard of care in one of healthcare’s largest unmet need disease states: heart failure and recovery.

Joaquin Duato, Chief Executive Officer of Johnson & Johnson said, “We have committed to enhancing our position in MedTech by entering high-growth segments. The addition of Abiomed provides a strategic platform to advance breakthrough treatments in cardiovascular disease and helps more patients around the world while driving value for our shareholders.”

2. Boston Scientific Announces Agreement to Acquire Apollo Endosurgery, Inc.

Boston Scientific Corporation announced its acquisition of Apollo Endosurgery, Inc. for a cash price of $10 per share, reflecting an enterprise value of approximately $615 million. The Apollo Endosurgery product portfolio includes devices used during endoluminal surgery (ELS) procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity.

"Endoluminal surgery is an emerging field and a core focus for our Endoscopy business," said Mike Jones, senior vice president and president, Endoscopy, Boston Scientific. "We intend to expand our global capabilities in ELS with the differentiated innovation that Apollo Endosurgery offers, and we will continue to focus on procedural adoption as well as professional education in this exciting space. This acquisition also enables us to enter a new adjacency – the endobariatric market – and deliver strong, continued growth across our business."

3. ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Management Software Solutions

ResMed announced it has completed its €958.6 million acquisition of MEDIFOX DAN, a German leader in software solutions for a wide variety of out-of-hospital care providers. This acquisition expands ResMed’s SaaS business to Germany, first non-U.S. market. ResMed intends to retain MEDIFOX DAN’s employees, locations, and business processes. MEDIFOX DAN will report into ResMed SaaS President Bobby Ghoshal.

4. Integra LifeSciences to acquire Surgical Innovation Associates

Integra LifeSciences signed a definitive agreement to buy Surgical Innovation Associates (SIA ), a spin-out from Northwestern University, Illinois, US. Under the deal terms, Integra will pay $50m at the closing of the deal, as well as up to $90m more upon achieving certain revenue and regulatory milestones. SIA develops advanced solutions for reconstructive and aesthetic surgery to improve the experience of both surgeons and patients. Integra LifeSciences expects the deal to advance its global strategy in breast reconstruction. It will also support the company’s plans to enter the US market with Food and Drug Administration (FDA)-approved devices that are designed for use in implant-based breast reconstruction (IBBR) procedures.